ASCO/EHA/ICML 2023 Look-back: CAR-T Remains King in DLBCL and MM
Impressive data from Yescarta and Carvykti set both CAR-T therapies up to extend leadership in DLBCL and MM, respectively
Executive Summary
Multiple CAR-T data sets were presented at the summer oncology conference series, confirming the long-term potential of CAR-T as a primary treatment modality in heme malignancies. P3 data from Yescarta (axi-cel; GILD) and Carvykti (cilta-cel; JNJ, LEGN) in earlier lines of therapy in DLBCL and MM, respectively, demonstrated major improvements in survival endpoints and will help cement CAR-T as SoC in these settings and GILD, JNJ/LEGN as market leaders in their particular spaces. GILD’s CD19 CAR-T franchise appears poised to usurp Roche’s CD20 mAb franchise in NHL, while JNJ continues to be well positioned to become the market leader in MM, pushing aside BMS.
Keep reading with a 7-day free trial
Subscribe to Big Pharma Sharma to keep reading this post and get 7 days of free access to the full post archives.